Therapeutics – Anticancer System Capable of Loco-regional Delivery of Drug Product

Privo Technologies, Inc. is focused on changing the oncology treatment paradigm with its Programmed Release Vehicle (PRV) technology....

Read more

Winner of the AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition Announced

Privo Technologies to Receive $900,000 of Investment Funding Privo Technologies and its chief executive officer, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s inaugural Women’s Venture Competition, a first of its kind program for female entrepreneurs starting oncology companies. Privo Technologies has developed a nano-engineered platform…...

Read more

Congratulations to our Top Two Finalists and the People’s Choice Award Winner!

Congratulations to the inaugural AIM-HI Women’s Venture Competition finalists selected by the Judging Committee, Stacy Blain of Concarlo Holdings and Manijeh Goldberg of Privo Technologies. Not only are they advancing science, but they are also paving the way for more women scientist-entrepreneurs. The AIM-HI Women’s Venture Competition also hosted a People’s Choice…...

Read more

Support Women Scientist-Entrepreneurs in Celebration of the Women’s Equality Day

It’s 2020, and still only 2.2% of all venture capital dollars go to companies led by women entrepreneurs in life sciences. Let’s change that! Join us on Thursday, September 24, at the AIM-HI Women’s Venture Competition Award Ceremony as we celebrate 8 leading-edge women entrepreneurs, each on the cusp of developing innovative therapies…...

Read more

AIM-HI Announces Semi-Finalists in Women’s Venture Competition, Finalists Announced Sept. 24

The 8 semi-finalists are just announced in the AIM-HI Accelerator Fund’s inaugural Women’s Venture Competition! These innovative oncology startups are selected from an exceptional pool of high quality women entrepreneur applications, by a Selection Committee comprised of world-class key opinion leaders, life sciences industry experts, investors, and entrepreneurs. The Women’s…...

Read more

Infection Threat from Asymptomatic COVID-19 Patients Around You

Michael Wang, MD., Ph.D., member of AFCR Scientific Advisory Board The recently announced extension of social distancing guidelines through the end of April is an important step taken by the U.S. federal government to slow down the spread of coronavirus. But the overall picture of the COVID-19 pandemic is still very…...

Read more

2018 USCACA-AFCR Young Investigator Award

The 2018 USCACA-AFCR Scholar Award Ceremony in Tianjin on November 17, 2018 The Asian Fund for Cancer Research and the US Chinese Anti-Cancer Association have jointly awarded six outstanding Chinese cancer researchers in the early stage of their careers with the 2018 USCACA-AFCR Young Investigator Award. Scholars will each receive…...

Read more

USCACA & AFCR 2018 Scholar Awards

The United States Chinese Anti-Cancer Association and AFCR are pleased to invite nominations for the USCACA-AFCR 2018 Scholar Awards. The Awards will recognize 4 to 5 junior Chinese investigators on the basis of significant contributions in Translational or Clinical Cancer Research. Candidacy is open to all Chinese researchers who were trained…...

Read more

7 Facts You Need to Know About Lung Cancer

With lung cancer continuing to affect the lives of so many people, it’s important to understand the disease and what we can do to improve our chances of beating it. 1. Targeted therapies are showing great promise in treating lung cancer. If you’ve been diagnosed with lung cancer, talk to…...

Read more

Determining the Risk of Hereditary Breast and Ovarian Cancer (HBOC) in China

Understanding the risk of breast cancer in the Chinese population is very important due to the exponential increase in incidence......

Read more